VJOncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology.
Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media – including video and blog formats.
VJOncology content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of cancers. All content is created and published under the guidance of this board of world-leading experts.
Updates in GU cancer at ESMO 2025: SunRISe-4, PSMAddition, and more
Educating healthcare teams for effective AI adoption in oncology
Educating clinicians to use and evaluate AI tools in oncology
Strategies to increase artificial intelligence literacy for oncologists
Evaluating the diagnostic capabilities of artificial intelligence in oncology
Developing agnostic artificial intelligence models for multiple cancer types
Challenges in integrating multimodal cancer AI models in clinical practice
The benefits and potential pitfalls of multimodal AI in oncology
SERDs in premenopausal breast cancer: improving outcomes & treatment options
What is the clinical significance of the ENZARAD trial in prostate cancer?
Novel bispecific antibodies, BITESs and ADCs for neuroendocrine carcinomas
Improving diagnosis & treatment selection in grade 3 neuroendocrine tumors
First and second line treatment of digestive neuroendocrine carcinoma
ENZARAD: ADT, radiotherapy and radical prostatectomy in prostate cancer
PSMA expression as a key predictor of response to PSMA lutetium therapy
Advances in reducing late toxicity in head & neck cancer treatment
Unmet needs and future directions in in head and neck cancer
GI cancer highlights at ESMO 2025: FORTITUDE-101, STELLAR-303, and more
Evaluating durvalumab and chemotherapy for MIBC in the NIAGARA trial
Refining ICI-based treatment selection in metastatic clear cell RCC